One-year increase in age at diabetes diagnosis linked to lower risk for all-cause mortality and macrovascular, microvascular disease
TUESDAY, Dec. 15, 2020 (HealthDay News) — Younger age at diagnosis of type 2 diabetes is associated with an increased risk for mortality and vascular disease, according to a review published online Dec. 14 in Diabetologia.
Natalie Nanayakkara, M.B.B.S., from Monash University in Melbourne, Australia, and colleagues examined the risk for mortality, macrovascular complications, and microvascular complications associated with age at type 2 diabetes diagnosis in a systematic review. Data were included from 26 observational studies, which included 1,325,493 individuals from 30 countries.
The researchers observed an inverse association between age at diabetes diagnosis and risk for all-cause mortality and macrovascular and microvascular diseases. After adjustment for current age, each one-year increase in age at diabetes diagnosis was associated with a 4, 3, and 5 percent reduction in the risks for all-cause mortality, macrovascular disease, and microvascular disease, respectively. For individual components of the composite outcome, the effects were consistent.
“This difference in risk between younger and older people in terms of absolute versus lifetime risks of type 2 diabetes complications should perhaps be recognized in diabetes management guidelines, with increased promotion of screening programs in older people with type 2 diabetes and a greater emphasis on preventive measures for younger people with type 2 diabetes,” Nanayakkara said in a statement.
Several authors disclosed financial ties to the biopharmaceutical industry.
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD
Report Highlights Substance Use in Young Adults in U.S. in 2025
Considerable Gaps Identified in LDL Cholesterol Control
Link Between Liver Fibrosis in MASLD, ASCVD Varies by Glycemic Status
Semaglutide Not Linked to Higher Neovascular Age-Related Macular Degeneration Risk